{"id":"W4221036987","doi":"10.1007/s12325-022-02097-2","title":"P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease","year":2022,"lang":"en","type":"review","venue":"Advances in Therapy","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Atuka (Canada); Toronto Western Hospital","funders":"Parkinsonfonden; Ipsen; H. Lundbeck A/S; Sage Therapeutics; Acorda Therapeutics; Sunovion; European Commission; Sanofi; University of South Florida; Israel Science Foundation; University of Cambridge; Boston Scientific Corporation; International Parkinson and Movement Disorder Society; Biogen; University of Oxford; Adamas Pharmaceuticals; Jazz Pharmaceuticals; National Parkinson Foundation; Teva Pharmaceutical Industries; AstraZeneca","keywords":"Rasagiline; Pramipexole; Tolerability; Levodopa; Medicine; Parkinson's disease; Selegiline; Pharmacology; Dopamine; Internal medicine; Adverse effect; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000164316,0.0005950214,0.001398726,0.0003655913,0.00009413983,0.0000212633,0.0001136935,0.0001137967,0.0001124027],"category_scores_gemma":[0.000044886,0.0004560116,0.0002796629,0.0003080578,0.00002968032,0.0001468149,0.00003642432,0.000171371,0.00000606144],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001138837,"about_ca_system_score_gemma":0.001191886,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003336693,"about_ca_topic_score_gemma":0.00008650715,"domain_scores_codex":[0.9976912,0.0001290113,0.0006307296,0.0008612066,0.0002620846,0.0004257344],"domain_scores_gemma":[0.9987754,0.0001718849,0.0002650949,0.0003900919,0.00001630805,0.000381177],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001072034,0.001328731,0.0003062577,0.00169764,0.0001751893,0.0002688048,0.0001123051,0.000006602724,2.647261e-7,0.0001007668,0.00001213308,0.9949193],"study_design_scores_gemma":[0.007537912,0.000663456,0.0007001117,0.002400252,0.0003205215,0.000018217,0.00002876747,0.00003445855,0.000004806829,0.0006761278,0.9872396,0.0003757584],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007723488,0.994287,0.0001286569,0.00005310155,0.0002017521,0.004337081,0.00009758973,0.00004718727,0.00007533855],"genre_scores_gemma":[0.0002903452,0.9890695,0.003580796,0.0001152545,0.000105452,0.005029837,0.0009282067,0.00008714807,0.0007934541],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9945435,"threshold_uncertainty_score":0.9997892,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06135916018494184,"score_gpt":0.3735306502470583,"score_spread":0.3121714900621164,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}